Frank Bennett, the chief scientific officer of Ionis Pharmaceuticals and one of the scientists present at the company's creation, is retiring after 37 years, according to Endpoints News.
Bennett joined Ionis as a founding scientist in 1989 and rose over the following decades to become the company's CSO. Endpoints reports that his retirement will take effect in February 2027, giving Ionis a long runway to plan for the transition rather than scrambling to fill the seat.
The same Endpoints report notes that Recursion has selected its first AI chief — a pairing that captures a generational handoff underway in drug discovery, where the leadership roles being created now often sit at the intersection of biology and computation.
A tenure like Bennett's is unusual in an industry where senior scientists routinely move between companies every few years. Founding scientists who stay long enough to run research at the company they helped start tend to carry an outsized share of its scientific direction — the judgment about which programs to back and which to kill, and the institutional memory of why earlier decisions were made the way they were. That kind of knowledge is difficult to write down and harder to replace.
The more than one-year notice period is itself a signal. Companies telegraph executive departures this far ahead when the role is central enough that investors and staff need time to absorb the news, and when a successor search is expected to take a while.
It matters because the person who has shaped Ionis' science since its founding is handing off, and who follows will influence what the company chooses to pursue for years after Bennett walks out the door.